Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

Pre and post-treatment mean EPG values on days 0, 7, 14, 21, and 28. by Sohail Afzal (10850709)

Subjects:

Correlation between protein abundances and R_5-20 z-score among cases at baseline. Protein abundances, normalized to mean 0 and variance 1, are displayed on the y-axis. (... by Spela Kokelj (8356644)

Subjects:

MiR-129-5p levels were decreased in mouse depression models. by Qiaozhen Qin (13159201)

“…(n = 3 - 10 mice per group; Data are presented as the mean ± standard error; *, **, ***, and **** indicate significance at p < 0.05, p < 0.01, p < 0.001, and p < 0.0001, respectively.).…”

Arm tremor and rigidity during settings (mean ± sd). by Verneri Ruonala (12419145)

Subjects:

Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i> by Razia Rashid Rahil (22772495)

“…Results are presented as mean ± SD. Ceramide: CER, Evogliptin: EVO. *(P < 0.05) significant vs. control group; ^$(P < 0.05) significant vs. …”

Increased osteoblastic activity and decreased osteoclastogenesis in TgLRAP cells <i>in vitro</i>. by Naoto Haruyama (487384)

“…Compared with the co-culture of WT BMCs and WT calvarial cells (WT / WT), the number of osteoclasts were significantly decreased at 50% in the co-cultures of TgLRAP BMCs and TgLRAP calvarial cells (TgLRAP / TgLRAP) (graph). …”

Mast cell density and tactile sensitivity decreased after 10 preventative imatinib treatments followed by repeated MI challenges. by Jaclyn M. Kline (9565161)

“…(B) Tactile sensitivity in sensitized mice preventatively treated with imatinib or NT and then 10 daily MI challenges. Results reported as mean ± SEM of the percent decrease from baseline in the withdrawal threshold for each treatment group, n = 18/treatment group. …”

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

Subjects:

Post-treatment CAPS score changes from clinical trials with off-label PTSD medications. by Filip Stanicic (17808254)

Subjects:

Treatment and outcome characteristics. by Manik Chhabra (10822587)

Subjects:

Significant interactions from mixed linear models of ECM colonization (Table 1). by Laura García de Jalón (8939456)

Clinical and laboratory measurements of patients with ALS (N = 13; Mean±SD; ns = not significant; nd = not determined; * = evidence of subgroup responsiveness). by Ann Logan (9361)

Prb1 overexpression decreased APCs in ESCRT-mutant cells after nitrogen starvation. by Zulin Wu (4451572)

“…The percentage of cells containing GFP in vacuoles (shown in panel A) was quantified as the mean +/- STD. Over 600 cells were counted for each strain. …”

Decreased clonogenic capacity of U87MG and U251MG glioma cells dependent on SHG-44 concentration. by Denis Mustafov (19137870)

“…<p><b>(A)</b> A significant decrease in the proliferative clonal capacity of U87MG colonies was observed with 70ΜM and 100ΜM SHG-44 treatment. …”

Transepithelial resistance of NHBE decreases significantly after PAA exposure. by Ellie S. Burns (21246537)

Average per capita transfer amounts in different countries. by Na Chen (153323)

Subjects:

Mean concentrations of sum monoterpenes and single monoterpenes: α-pinene, β-pinene, myrcene, limonene, β-(E)-ocimene, and α-terpineol obtained from the 10 distillation time (DT) f... by Valtcho D. Zheljazkov (627617)

Figures. by Remi Yoshikata (11419275)

Subjects: